Reproductive Medicine Associates of Texas (RMATX) and INVO Bioscience Announce Positive Patient Results Using the INVO Procedure
MEDFORD, Mass. and SAN ANTONIO, Nov. 18, 2016 — INVO Bioscience, Inc. (OTC: IVOB), a reproductive medical device company who was granted FDA clearance for the first Intravaginal Culture System, the INVOcell™, and Reproductive Medicine Associates of Texas (RMATX) today announced positive results of their initial eleven patients to receive the INVO™ procedure using the INVOcell device.
Dr. Francisco Arredondo of RMATX announced that he has nine (9) clinical pregnancies out of his first eleven (11) patients who have received the INVO procedure for treatment of infertility, or an 82% clinical pregnancy rate.
“I am extremely pleased with the results of the INVO procedure, and the patients have been very receptive to this new procedure,” commented Dr. Arredondo. “Patients perceive it as more organic and natural. We see very high quality embryo’s using the INVOcell, which has resulted in high pregnancy rates.”
Dr. Arredondo has been using the INVOcell in conjunction with a low ovarian stimulation protocol at 40% reduced cost compared to traditional IVF.
Dr. Arredondo is among the first physicians to adopt the INVO procedure in his practice. His team began a startup company in South Texas specifically focused on increasing the access to underserved communities due to economic barriers. S.M.A.R.T. IVF (Simple. Mindful. Affordable. Reproductive. Technology.) opened its doors in McAllen, Texas in October 2016.
Dr. Arredondo continued, “S.M.A.R.T. IVF is looking to increase the access to the dream of a family to people that before were unable to achieve due to cost barriers. We want to democratize fertility care.”
The patented INVO Procedure, is a fertility treatment that streamlines care, contributing to lower treatment costs compared to traditional IVF. Unlike conventional infertility treatments such as in vitro fertilization (IVF), where the eggs and sperm develop into embryos in a laboratory petri dish, the INVOcell utilizes the women’s body as a natural incubator making it an in vivo procedure. The INVO fertility treatment in clinical studies produced live birth rates equivalent to traditional IVF while adding the benefits of a more natural, simpler and lower cost treatment.
“INVO Bioscience is thrilled to be partnering with Dr. Arredondo at RMATX, and we are exceedingly impressed with his very high clinical pregnancy rate,” commented Katie Karloff, CEO of INVO Bioscience.
About RMA of Texas
RMA of Texas offers a unique, individualized approach to fertility care and tailors your fertility treatments to you. RMA of Texas provides a wide array of treatment options including IVC (Intravaginal Culture), IVF (In-Vitro Fertilization), IUI (Intrauterine Insemination), and ICSI (Intracytoplasmic Sperm Injection) that are tailored to the individual by our Reproductive Endocrinologists.
About INVO Bioscience
INVO Bioscience (IVOB) is a medical device company, headquartered in Medford, MA, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company’s lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman’s vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit www.invobioscience.com.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT: Kathleen Karloff, CEO, INVO Bioscience, 978-878-9505 ext. 504, Dr. Francisco Arredondo, RMA of Texas, 210-FERTILE